Navigation Links
Gene variations that alter key enzyme linked to prostate cancer
Date:10/1/2010

Researchers at the National Institutes of Health have found that variations in a gene for an enzyme involved in cell energy metabolism appear to increase the risk for prostate cancer.

The genetic variations all impair the enzyme phosphodiesterase 11A (PDE11A), which helps regulate a cell's responses to hormones and other signals. Previous studies by NIH researchers have linked genetic variations that inactivate PDE11A with increased susceptibility to testicular cancer and adrenal tumors

The researchers found that a group of men with prostate cancer were nearly four times more likely to have variations affecting the activity of PDE11A than did men who did not have prostate cancer. In 2010, it is estimated that there will be 217,730 new cases of prostate cancer, and 32,050 deaths (http://www.cancer.gov/cancertopics/types/prostate).

"Our study indicates that PDE11A one day may have a place in genetic screening for predisposition to prostate cancer," said the senior author of the study, Constantine Stratakis, M.D., D.Sc., acting director of the Intramural Research program at NIH's Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

Dr. Stratakis's research team included colleagues at the NICHD, first author Fabio Rueda Faucz and colleagues from the Pontifical Catholic University of Parana, Brazil; the Cochin Institute in Paris; and A.C. Camargo Hospital in Sao Paulo. The investigators also received support from the Parana State Secretariat of Science, Technology and Higher Education.

The findings were published online in the Journal of Clinical Endocrinology and Metabolism.

The researchers examined tissue from 50 men with prostate cancer and 287 men who did not have prostate cancer. The researchers analyzed the DNA of the men and found 8 variations in the PDE11A gene that decreased the production or activity of PDE11A. Of the men with prostate cancer, 30 percent had one or more of these variations, compared with 10 percent of the men who did not have prostate cancer. Of the variations the researchers detected, 5 had been detected in previous studies and 3 were previously unknown.

Dr. Stratakis explained that phosphodiesterase enzymes, of which there are nearly a dozen, regulate cellular activity in hormone producing organs such as the testes, prostate gland, adrenal gland and ovaries. PDE11A regulates cyclic adenosine monophosphate, a compound involved in supplying cells with energy.

Tadalafil, a drug used to treat erectile dysfunction, also inhibits PDE11A. The researchers called for future studies to determine if tadalafil or other drugs that inhibit PDE11A might affect the prostate in men who have a variant gene for PDE11A.

There is no current clinical evidence to date linking tadalafil to prostate cancer or to other cancers.


'/>"/>

Contact: Robert Bock
bockr@mail.nih.gov
301-496-5133
NIH/National Institute of Child Health and Human Development
Source:Eurekalert

Related biology news :

1. U of MN study shows link between gene variations and cancer survival
2. Scientists uncover new genetic variations linked to psoriasis
3. The genetics of fear: Study suggests specific genetic variations contribute to anxiety disorders
4. Study finds variations in 1 gene may be associated with endurance running
5. Variations on the genetic theme
6. Rare and common genetic variations responsible for high triglyceride levels in blood
7. Alternative to burning: environmentally sound disposal for wood chips
8. During exercise, the human brain shifts into high gear on alternative energy
9. Earthworm activity can alter forests carbon-carrying capabilities
10. Social interactions can alter gene expression in the brain, and vice versa
11. Turtles alter nesting dates due to temperature change says ISU researcher
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... March 21, 2017 Optimove , ... by retailers such as 1-800-Flowers and AdoreMe, today ... Recommendations and Replenishment. Using Optimove,s machine learning algorithms, ... product and replenishment recommendations to their customers based ... predictions of customer intent drawn from a complex ...
(Date:3/16/2017)... - Against identity fraud with DERMALOG solutions "Made in Germany "  ... ... multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog Identification Systems) ... Used combined in one project, multi-biometric solutions provide a crucial contribution against identity ... ...
(Date:3/7/2017)... Brandwatch , the leading social intelligence company, today announces that it ... insights to support its reporting, help direct future campaigns, and share ... charity will be using Brandwatch Analytics social listening and analytics technology ... the topics and issues that are a priority for its supporters. ... "Until recently we,ve ...
Breaking Biology News(10 mins):
(Date:3/27/2017)... , March 27, 2017 Neurotrope, Inc. ... therapies for neurodegenerative diseases, including Alzheimer,s disease, today ... application to list the Company,s common stock on ... The NASDAQ Stock Market, a unit of the ... will ring the Opening Bell at the NASDAQ ...
(Date:3/24/2017)... , March 24, 2017 ... the trading session at 5,817.69, down 0.07%; the Dow ... 20,656.58; and the S&P 500 closed at 2,345.96, marginally ... 4 sectors closed in green, 4 sectors finished in ... This Friday, Stock-Callers.com has initiated reports coverage on the ...
(Date:3/23/2017)... Research and Markets has announced the ... to their offering. ... The Global Market for Bioproducts Should Reach ... a CAGR of 8.9%, This research report ... seven major product segments: bio-derived chemicals, biofuels, pharmaceuticals (biodrugs and ...
(Date:3/23/2017)... ... March 23, 2017 , ... Ellen ... the Connecticut Technology Council (CTC) as a 2017 Women of Innovation® finalist. Matloff ... of Innovation Awards Dinner. , The dinner recognizes women accomplished in science, technology, ...
Breaking Biology Technology: